While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (A/MBC), the most commonly diagnosed subtype globally. The introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) – palbociclib, ribociclib, and abemaciclib – has marked a significant advancement in the first-line treatment of this disease.
Through an updated systematic literature review, Nadia Harbeck, MD; Adam Brufsky, MD; Timothy Pluard, MD; the team at Pfizer (Chloe Grace Rose, Beata Korytowsky, Connie Chen); and the Value & Evidence team at EVERSANA (Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo) provide an understanding of the growing body of RWE surrounding the use of first-line CDK4/6i in HR+/HER2− A/MBC.
RWE on first-line CDK4/6i shows significant clinical benefits in this population. These findings are crucial for guiding clinical decisions, as they encompass patients who are underrepresented in clinical trials.
For a deeper understanding, access the Frontiers in Oncology article here.
Author
Sofiya joined the Value & Evidence division of EVERSANA in 2021 as a Research Assistant. At EVERSANA, Sofiya has supported systematic and targeted literature reviews across various disease areas, such as various cancers, pulmonary…